Hazel M. Weir

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.6kcitations64works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(35), HER2/EGFR in Cancer Research(11), Advanced Breast Cancer Therapies(9), Angiogenesis and VEGF in Cancer(8), Cancer therapeutics and mechanisms(8)

Publications64 total

Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Data from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
2023Open Access
Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Figures 1 - 8, Tables 1 - 3 from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
2023Open Access
Supplementary Methods from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
2023Open Access
Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Figures 1 - 8, Tables 1 - 3 from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
2023Open Access
Data from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
2023Open Access
Supplementary Methods from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
2023Open Access
Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Table S1 from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
Data from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
Figure S2A and S2B: Geometric mean plasma concentration-time profiles of AZD9496 metabolites M3 (A and B) and M5 (C and D) following a single dose and multiple doses of AZD9496 (n = 3-5 subjects) from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
Figure S1: Doses given and DLTs experienced in the dose escalation and dose expansion cohorts from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
Table S2 from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
Figure S2C and S2D: Geometric mean plasma concentration-time profiles of AZD9496 metabolites M3 (A and B) and M5 (C and D) following a single dose and multiple doses of AZD9496 (n = 3-5 subjects) from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
Figure S2C and S2D: Geometric mean plasma concentration-time profiles of AZD9496 metabolites M3 (A and B) and M5 (C and D) following a single dose and multiple doses of AZD9496 (n = 3-5 subjects) from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
Figure S2A and S2B: Geometric mean plasma concentration-time profiles of AZD9496 metabolites M3 (A and B) and M5 (C and D) following a single dose and multiple doses of AZD9496 (n = 3-5 subjects) from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Anne Marie Mazzola(14), Mandy Lawson(13), Jon Curwen(12), Celina M. D’Cruz(12), Robert H. Bradbury(11), Zena Wilson(11), Chris De Savi(11), Alfred A. Rabow(10), David Buttar(10), Rowena Callis(10), Peter Ballard(10), Craig S. Donald(10), Richard A. Norman(10), Michael Tonge(10), Graeme E. Walker(10), Ermira Pazolli(10), Erika Hamilton(10), Richard D. Baird(10), Matthias Hoch(10), Teresa Klinowska(10)